Abstract: Disclosed are methods for lysis of cells that combine three lysis steps—(1) heat, (2) detergent and (3) base—into a single step and that can be completed in a short period of time, e.g., a few minutes. The methods combine a normally incompatible detergent and base lysis, allow for simplified removal of detergent after lysis, and importantly, limits damage to DNA, such as shearing, that typically results from separate application of conventional lysis methods, yielding improved quality and quantities of genomic DNA (gDNA).

Abstract: A method to divide liposuction fat into aliquots for use and cryopreservation purposes, the method comprising: providing a taking container that contains adipose material removed by liposuction, the adipose material including fat and aqueous fluid; providing a plurality of cryopreservation containers; taking a quantity of the adipose material from the taking container, keeping the quantity of the adipose material isolated from an external environment; separating by gravity the fat from the aqueous fluid in the adipose material of the taken quantity; and transferring the separated fat into one or more cryopreservation containers, to define isolated aliquots of fat.

Abstract: A method of detecting prometastatic cancer activity in the liver of a patient suffering from colorectal cancer, as well as a method of diagnosing and treating colorectal cancer according to primary tumor location, based on divergent expression levels and functional classification of specific genes in tumor unaffected hepatic tissue. Specific genes include statistically significant ones of group 1 genes PRDX4, CRP, ID1, MT1E, TNFSF14, MRC1, ICAM1, IL18, IL10, TFN; group 2 genes NGF, EPHA1, ERBB2IP, SDC1, COL18A1, KNG1, ADH1B, CYP2E1; and group 3 genes HP, VTN, RPS27, RPL23, GAPDH, TXN, VEGFA, CEACAM1, IGF1, TGFB1, DDR2, NOS2, and BMP7.

Abstract: Rule-based apparatus and kit to detect metastatic cancer in a patient having a colorectal tumor. Apparatus has inputs to receive patient data comprising expression levels of genes from hepatic tissue, a memory that stores reference values of corresponding genes of persons free of colorectal tumors, a processor that interprets significance of overexpression and/or underexpression of selected patient data genes relative to reference values, and an output responsive to the processor to produce an indication confirming or annulling hepatic metastasis. Specific genes in questions include group 1 genes (PRDX4, CRP, ID1, MT1E, TNFSF14, MRC1, ICAM1, IL18, IL10, TFN) and group 2 genes (NGF, EPHA1, ERBB2IP, SDC1, COL18A1, KNG1, ADH1 B, CYP2E1). Analysis may be performed on protein signatures of genes rather than genes themselves.

Abstract: The invention relates to the production of phage and transduction particles using DNAs (eg, plasmids and helper phage, mobile genetic elements (MGEs) or plasmids with chromosomally integrated helper phage genes), as well as the phage, helper phage, kits, compositions and methods involving these.

Abstract: A device to simulate a surface bleeding is provided. The device includes A source of a blood liquid; A pump system connected to the source of blood liquid and configured to provide a controlled flow of said blood liquid; A wound simulator having an open chamber connected to the pump system to receive the controlled flow of blood liquid, wherein the wound simulator includes a set of interchangeable plates having a plurality of holes arranged through said plates according to a specific pattern, and each plate being adapted to be removably mounted on the wound simulator to close the open chamber, so that blood liquid flows out of the chamber through the holes of the plate mounted on the wound simulator.

Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.

Abstract: A system (1) to divide liposuction fat into aliquots, comprising taking means (2, 3) to take from a container a quantity of adipose material, made available by means of liposuction, and to preserve sealed the quantity taken, the system (1) also comprising at least a separation syringe (4) able to be put in communication with said taking means (2, 3), and able to contain at least a portion of said quantity, the separation syringe (4) being provided so as to separate, by gravity, the fat from the aqueous fluids composing the adipose material, first connection means (5) to put in sealed communication the taking means (2, 3) with the separation syringe (4), at least a rejection container (6), able to be put in communication with the separation syringe (4) so as to receive the aqueous fluids, following their ejection from the separation syringe (4), at least a syringe device (7, 8) able to be put in sealed communication with the separation syringe (4) so as to receive an aliquot of fat, following its ejection from

Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.

Abstract: Antibodies that specifically bind TEM8 protein, conjugates thereof, and their use, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.

Abstract: The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

Abstract: The present invention relates to relaxin or a homologue or variant thereof for use in a method of treating an inflammatory condition, for example an autoimmune inflammatory condition. The invention also relates to the treatment of an inflammatory condition, for example an autoimmune inflammatory condition comprising administering to a subject in need thereof a relaxin, or a homologue or variant thereof. Such conditions may be CNS conditions or be organ specific.

Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.

Abstract: Monitoring, analysis and control of fermentation activities includes methods and corresponding systems directed toward agriculture, biofuels, and food production. Complex methods and corresponding systems are provided for classifying a microorganism; profiling a microbiome; sequencing multiple libraries in a single sequencing run; determining a microbiome profile in a sample; and analyzing a material from a location associated with a fermentation process. Additional implementations are directed to methods and corresponding systems for obtaining, deriving, predicting and evaluating microbiome information; control, analysis and direction of fermentation operations; and evaluating, analyzing and displaying microbiome related information in two and three dimensional plots. Yet additional methods and corresponding systems permit identification and analysis of microorganisms capable of imparting beneficial properties to phases of fermentation processes.

Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.

Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virususing the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virusinfection in a subject.

Abstract: The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

Abstract: Topical formulations containing erythropoietin (EPO), and also preferably fibronectin (FN), especially gel formulations, are used to accelerate wound healing, e.g., from a burn, compared to the healing process without such a formulation being applied. Methods of preparing the formulations are also provided.

Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.

Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both group A and group B RSV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV infection and group A and group B RSV co-infection.